“Celiac Disease Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Celiac Disease Market.
The Celiac Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Celiac Disease Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for the treatment of Celiac Disease and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Celiac Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like -
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
Celiac Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Celiac Disease Products have been categorized under various ROAs such as
-
Intra-articular
-
Intraocular
-
Intrathecal
-
Intravenous
-
Ophthalmic
-
Oral
-
Parenteral
-
Subcutaneous
-
Topical
-
Transdermal
Molecule Type
Celiac Disease Products have been categorized under various Molecule types such as
-
Oligonucleotide
-
Peptide
-
Small molecule
Mechanism of Action of the Emerging Pipeline Therapies
-
Cell membrane permeability inhibitors
-
Interleukin 15 inhibitors
-
Immunomodulators
Learn How the Ongoing Clinical & Commercial Activities will Affect the Celiac Disease Therapeutic Segment @
https://www.delveinsight.com/sample-request/celiac-disease-pipeline-insight
Celiac Disease Therapeutics Landscape
There are approx. 25+ key companies which are developing therapies for Celiac Disease. Currently, 9 Meters Biopharma is leading the therapeutics market with its Celiac Disease drug candidates in the most advanced stage of clinical development.
The Leading Players in the Celiac Disease Therapeutics Market Include:
-
9 Metres Biopharma
-
ActoBio Therapeutics
-
Amgen
-
Amyra biotech
-
Anokion
-
Calypso Biotech
-
GlaxoSmithKline
-
ImmunogenX
-
ImmusanT
-
Millennium Pharmaceuticals
-
Takeda
-
Zedira GmbH
-
Allero Therapeutics
And Many Others
Celiac Disease Emerging and Marketed Drugs Covered in the Report Include:
-
AG017: Precigen ActoBio
-
ALL-001: Allero Therapeutics
-
AMG-714/PRV-015: Amgen
-
BNZ-2: Bioniz
-
CALY 002: Calypso Biotech
-
CNP- 101: Cour Pharmaceutical
-
KAN 101: Anokion
-
Larazotide Acetate (INN-202/AT-1001): 9 Meters Biopharma
-
Latiglutenase (IMGX003/ALV003): ImmunogenX
-
Ordesekimab - Amgen
-
PRV-015: Provention Bio
-
TAK-101: Takeda/Cour Pharmaceuticals
-
ZED1227: Falk Pharma and Zedira
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
https://www.delveinsight.com/sample-request/celiac-disease-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Celiac Disease Current Treatment Patterns
4. Celiac Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Celiac Disease Late Stage Products (Phase-III)
7. Celiac Disease Mid-Stage Products (Phase-II)
8. Celiac Disease Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Celiac Disease Discontinued Products
13. Celiac Disease Product Profiles
14. Key Companies in the Celiac Disease Market
15. Key Products in the Celiac Disease Therapeutics Segment
16. Dormant and Discontinued Products
17. Celiac Disease Unmet Needs
18. Celiac Disease Future Perspectives
19. Celiac Disease Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/celiac-disease-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
The global Breast Pumps Market was valued at USD 1,081.96 million in 2021, growing at a CAGR of 8.67% during the forecast period (2023-2028); it is expected to reach USD 1,776.50 million by 2028. The Breast Pumps Market is witnessing positive growth owing to various key factors such as the surge in the number of employed mothers, technological advancements in the product offering, changes in consumer lifestyle, and increasing awareness for breast pumps thereby, among others.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
